摘要
Abstract
OBJECTIVE: To evaluate the cost-effectivness of Salviae miltiorrhizae and ligustrazine hydrochloride injection combined with irbesartan in the treatment of diabetic nephropathy. METHODS: 76 cases of patients with diabetic nephropathy were randomly divided into treatment group and control group, 38 cases in each group. Based on the positive control blood sugar, the treatment group on the basis of continuous oral irbesartan tablets + Salviae miltiorrhizae and ligustrazine hydrochloride injection, ivgtt. (use 14 d), the control group was treated with oral irbesartan tablets for 12 weeks, observed before and after treatment, blood pressure, BUN, Scr, TG, TC, HDL-C, UAER, to analyze and compare the cost-effectiveness. RESULTS: Compared with before treatment in both groups, blood pressure, BUN, Scr and UAER were significantly decreased (P<0.05 or P<0.01), the treatment group compared with the control group decreased more significantly(P<0.01). After treatment, TG, TC significantly decreased, HDL-L increased (P<0.01), before and after treatment of the control group had no significant change (P>0.05). The treatment group and the control group, the total efficiency were 89.47% and 65.79%, respectively (P<0.05), the cost were (6 468.34±2 376.53 yuan and (5 482.64±486.67) yuan, cost-effectiveness ratio were 7 229.62 and 8 333.55, respectively. To the control group as a reference, the incremental cost-effectiveness of the treatment group was 41.63. CONCLUSIONS: Salviae miltiorrhizae and ligustrazine hydrochloride injection combined with Irbesartan in the treatment of diabetic nephropathy can lower blood pressure , reduce proteinuria, lower TG, TC, UAER in increasing HDL-C, stable renal function, more effective than the single use of irbesartan, and is a good combination, cost-effectiveness analysis results had no significantly increase.关键词
厄贝沙坦/丹参川芎嗪注射液/糖尿病肾病/成本-效果分析Key words
Irbesartan/ Salviae miltiorrhizae and ligustrazine hydrochloride injection/ Diabetic nephropathy/ Cost-effectiveness analysis分类
医药卫生
